MX2009011900A - Curacion de herida diabetica. - Google Patents

Curacion de herida diabetica.

Info

Publication number
MX2009011900A
MX2009011900A MX2009011900A MX2009011900A MX2009011900A MX 2009011900 A MX2009011900 A MX 2009011900A MX 2009011900 A MX2009011900 A MX 2009011900A MX 2009011900 A MX2009011900 A MX 2009011900A MX 2009011900 A MX2009011900 A MX 2009011900A
Authority
MX
Mexico
Prior art keywords
certain
wound healing
pharmaceutically acceptable
acceptable salt
additional therapeutic
Prior art date
Application number
MX2009011900A
Other languages
English (en)
Inventor
Jack R Barber
Original Assignee
Cytrx Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corp filed Critical Cytrx Corp
Publication of MX2009011900A publication Critical patent/MX2009011900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención proporciona métodos para mejorar la curación de heridas asociadas con diabetes, que comprenden administrar una cantidad efectiva de uno o más de ciertos derivados de hidroxilamina a un sujeto con la necesidad de esto. La invención también proporciona composiciones farmacéuticas que comprenden cierto derivado de hidroxilamina o una sal farmacéuticamente aceptable del mismo, opcionalmente en combinación con uno o más agentes terapéuticos adicionales. En ciertas composiciones y métodos, el agente terapéutico adicional es un segundo derivado de hidroxilamina o una sal farmacéuticamente aceptable del mismo.
MX2009011900A 2007-05-04 2008-05-05 Curacion de herida diabetica. MX2009011900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92760307P 2007-05-04 2007-05-04
PCT/US2008/005794 WO2008137149A1 (en) 2007-05-04 2008-05-05 Diabetic wound healing

Publications (1)

Publication Number Publication Date
MX2009011900A true MX2009011900A (es) 2010-01-20

Family

ID=39758710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011900A MX2009011900A (es) 2007-05-04 2008-05-05 Curacion de herida diabetica.

Country Status (8)

Country Link
US (1) US20090227572A1 (es)
EP (1) EP2152257A1 (es)
JP (1) JP2010526144A (es)
AU (1) AU2008248139A1 (es)
CA (1) CA2686063A1 (es)
MX (1) MX2009011900A (es)
TW (1) TW200901958A (es)
WO (1) WO2008137149A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
CA2743782A1 (en) * 2008-11-18 2010-05-27 Santen Pharmaceutical Co., Ltd. Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde o-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
EP3626255A1 (en) 2010-11-30 2020-03-25 Orphazyme A/S Methods for increasing intracellular activity of hsp70
CN103804309B (zh) * 2012-11-09 2019-08-02 广州喜鹊医药有限公司 一种氯肟类化合物及其制备方法和在制药中的应用
ES2881860T3 (es) * 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
US10660851B2 (en) 2015-01-02 2020-05-26 Rxos Medical Polyfunctional radical scavenger hydrogel formulation
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
AU2021380947B2 (en) 2020-11-19 2023-12-14 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride

Also Published As

Publication number Publication date
CA2686063A1 (en) 2008-11-13
EP2152257A1 (en) 2010-02-17
US20090227572A1 (en) 2009-09-10
WO2008137149A1 (en) 2008-11-13
JP2010526144A (ja) 2010-07-29
TW200901958A (en) 2009-01-16
AU2008248139A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2009011900A (es) Curacion de herida diabetica.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
MX2009005798A (es) Recuperacion de apoplejia.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
HK1176318A1 (en) Injection device
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
TNSN08506A1 (en) Substituted carboxamides
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal